Investors will test whether softness in key Southeast Asian markets signals broader demand risk or remains isolated.

Tachibana provided third quarter 2025 guidance of total company revenue in the range of $12 million to $14 million and pharma test/services revenue in the range of $11 million to $13 million.

CEO Guillaume Marie Jean Rutten reported second quarter revenue of $1.51 billion, a 14% sequential increase, stating "all end markets showing double-digit sequential growth." Rutten highlighted that ...